Explore more publications!
Health World Mauritania
Submit Press Release

Health World Mauritania: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health World Mauritania.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on September 10, 2025

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit
September 10, 2025

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

Indeterminate GlobeNewswire
OrthoPediatrics Corp. Completes First Procedures with VerteGlide™ Spinal Growth Guidance System
September 10, 2025

OrthoPediatrics Corp. Completes First Procedures with VerteGlide™ Spinal Growth Guidance System

Indeterminate GlobeNewswire
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
September 10, 2025

Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)

Indeterminate GlobeNewswire
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
September 10, 2025

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

Indeterminate GlobeNewswire
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
September 10, 2025

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

Indeterminate GlobeNewswire
Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25
September 10, 2025

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Indeterminate GlobeNewswire
Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand
September 10, 2025

Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand

Indeterminate GlobeNewswire
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
September 10, 2025

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

Indeterminate GlobeNewswire
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
September 10, 2025

Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation

Indeterminate GlobeNewswire
Medāna Brings Its Risk-Based AI Platform to Poland, Advancing Patient-Centered Healthcare Across Europe
September 10, 2025

Medāna Brings Its Risk-Based AI Platform to Poland, Advancing Patient-Centered Healthcare Across Europe

Indeterminate GlobeNewswire
Medāna uruchamia w Polsce swoją platformę analizy ryzyka bazującą na sztucznej inteligencji – poszerzając ofertę zorientowanej na pacjenta opieki medycznej w całej Europie
September 10, 2025

Medāna uruchamia w Polsce swoją platformę analizy ryzyka bazującą na sztucznej inteligencji – poszerzając ofertę zorientowanej na pacjenta opieki medycznej w całej Europie

Indeterminate GlobeNewswire
Fangzhou and Innovent Biologics Form Strategic Alliance for AI-Powered Weight Management Solutions
September 10, 2025

Fangzhou and Innovent Biologics Form Strategic Alliance for AI-Powered Weight Management Solutions

Indeterminate GlobeNewswire
IPG Health expands Influencer ID marketing expertise into Europe
September 10, 2025

IPG Health expands Influencer ID marketing expertise into Europe

Indeterminate GlobeNewswire
Asabys Partners Leads €10 Million Extension of SafeHeal’s Oversubscribed Series C Financing to Accelerate Commercialization of Colovac®
September 10, 2025

Asabys Partners Leads €10 Million Extension of SafeHeal’s Oversubscribed Series C Financing to Accelerate Commercialization of Colovac®

Indeterminate GlobeNewswire
Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
September 10, 2025

Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes

Indeterminate GlobeNewswire
Communiqué de presse : Tzield approuvé en Chine comme premier traitement modificateur de la maladie pour les patients adultes et pédiatriques atteints de diabète de type 1 au stade 2
September 10, 2025

Communiqué de presse : Tzield approuvé en Chine comme premier traitement modificateur de la maladie pour les patients adultes et pédiatriques atteints de diabète de type 1 au stade 2

Indeterminate GlobeNewswire
Pharming Group promoted to the Euronext AMX® index
September 10, 2025

Pharming Group promoted to the Euronext AMX® index

Indeterminate GlobeNewswire
Bioversys Reports Corporate Highlights and Key Financials For the First Half 2025
September 10, 2025

Bioversys Reports Corporate Highlights and Key Financials For the First Half 2025

Indeterminate GlobeNewswire
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
September 10, 2025

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

Indeterminate GlobeNewswire
Rapport Announces Pricing of Public Offering of Common Stock
September 10, 2025

Rapport Announces Pricing of Public Offering of Common Stock

Indeterminate GlobeNewswire

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions